PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-0.49%
Cost reduction while Biotechnology median is 0.00%. Seth Klarman would investigate competitive advantage potential.
0.49%
Growth of 0.49% versus flat Biotechnology gross profit. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
-36.64%
R&D reduction while Biotechnology median is -0.53%. Seth Klarman would investigate competitive implications.
-70.64%
G&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-54.90%
Operating expenses reduction while Biotechnology median is -0.69%. Seth Klarman would investigate advantages.
-54.90%
Total costs reduction while Biotechnology median is -2.62%. Seth Klarman would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
D&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency.
54.90%
EBITDA change of 54.90% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
54.90%
Income change of 54.90% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
-10.71%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
56.85%
Income change of 56.85% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
56.85%
Net income growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
56.86%
EPS growth exceeding 1.5x Biotechnology median of 2.38%. Joel Greenblatt would investigate advantages.
56.86%
Diluted EPS growth exceeding 1.5x Biotechnology median of 2.27%. Joel Greenblatt would investigate advantages.
-0.00%
Share count reduction while Biotechnology median is 1.70%. Seth Klarman would investigate strategy.
-0.00%
Diluted share reduction while Biotechnology median is 1.90%. Seth Klarman would investigate strategy.